Bristol Myers Squibb announced that mezigdomide, an oral targeted protein degrader from its CELMoD platform, produced a statistically significant and clinically meaningful improvement in progression‑free survival in relapsed/refractory multiple myeloma in a late‑stage study. The company said safety aligned with known profiles for the regimen components and pitched the result as validation of its targeted protein degradation strategy. Mezigdomide is one of several next‑generation CELMoDs BMS acquired through prior transactions and is being developed as a successor to older immunomodulatory agents. The announcement reduces development risk ahead of full data presentations and supports the company’s broader strategy to offset near‑term patent cliffs on legacy hematology products.